Drug Trial Radar · NCT04752215
A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface
Last checked: Nov 19, 2026Latest source record: Feb 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
67
Actual
Start
May 18, 2021
Primary completion
Nov 19, 2024
Study completion Dec 17, 2024
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Feb 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with advanced solid tumors whose previous cancer treatment was not successful. People can participate if their tumor has the B7-H6 marker or if they have colorectal cancer. The study tests 2 medicines called BI 765049 and ezabenlimab (BI 754091). Both medicines may help the immune system fight cancer. The purpose of this study is to find out the highest dose of BI 765049 alone and in combination with ezabenlimab the participants can tolerate. In this study, BI 765049 is given to people for the first time. Participants can stay in the study for up to 3 years, if they benefit from treatment and can tolerate it. During this time, they get BI 765049 alone or in combination with ezabenlimab as infusion into a vein every 3 weeks. The doctors check the health of the participants and note any health problems that could have been caused by BI 765049 or ezabenlimab. The doctors also regularly monitor the size of the tumor.
Conditions
- Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms
Interventions
BI 765049Drug
BI 765049
ezabenlimabDrug
ezabenlimab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD) in any studied regimenTime frame: Up to 3 weeks
- Number of patients with dose limiting toxicities (DLTs) in the maximum tolerated dose (MTD) evaluation periodTime frame: Up to 3 weeks
Locations
14 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Valkyrie Clinical Trials
Los Angeles, California
University of California Irvine
Orange, California
HealthONE
Denver, Colorado
MD Anderson Cancer Center Orlando
Orlando, Florida
Florida Cancer Specialists-Sarasota-61670
Sarasota, Florida
Northwestern University
Chicago, Illinois
Norton Healthcare - Norton Cancer Institute - Louisville
Louisville, Kentucky
New York University Langone Medical Center
New York, New York
Stephenson Cancer Center
Oklahoma City, Oklahoma
Tennessee Oncology, PLLC-Nashville-52568
Nashville, Tennessee
Mary Crowley Cancer Research Center
Dallas, Texas
Baylor University Medical Center
Dallas, Texas
Princess Margaret Cancer Centre
Toronto, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.